Cognition Therapeutics, Inc. (CGTX)
NASDAQ: CGTX · Real-Time Price · USD
0.7056
-0.0338 (-4.57%)
Oct 30, 2026, 1:54 PM EDT - Market open
Cognition Therapeutics Employees
Cognition Therapeutics had 14 employees as of December 31, 2025. The number of employees decreased by 14 or 50.00% compared to the previous year. That makes Cognition Therapeutics the 39,313th largest employer in the world and 5,770th in the United States.
Employees
14
Change (1Y)
-14
Growth (1Y)
-50.00%
Revenue / Employee
n/a
Profits / Employee
-$1,198,214
Market Cap
67.10M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 14 | -14 | -50.00% | 14 | 0 |
| Dec 31, 2024 | 28 | 0 | - | 25 | 3 |
| Dec 31, 2023 | 28 | 3 | 12.00% | 25 | 3 |
| Dec 31, 2022 | 25 | 4 | 19.05% | 22 | 3 |
| Dec 31, 2021 | 21 | 1 | 5.00% | 19 | 2 |
| Sep 30, 2021 | 18 | -2 | -10.00% | 15 | 3 |
| Jun 30, 2021 | 22 | - | - | 18 | 4 |
| Mar 31, 2021 | 22 | - | - | 20 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Champions Oncology | 214 |
| Acrivon Therapeutics | 76 |
| Neumora Therapeutics | 63 |
| Cardiff Oncology | 31 |
| Spero Therapeutics | 25 |
| Nutriband | 13 |
| MAIA Biotechnology | 13 |
| MediciNova | 6 |
CGTX News
- 8 days ago - Cognition Therapeutics aligns with FDA on Phase 3 trial of zervimesine - TheFly
- 8 days ago - Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies - GlobeNewsWire
- 17 days ago - Cognition Therapeutics issued patent covering novel crystalline form UPSTO - TheFly
- 17 days ago - Cognition Therapeutics issued patent extending protection for zervimesine - TheFly
- 17 days ago - Cognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (CT1812) Through 2045 - GlobeNewsWire
- 4 weeks ago - Cognition Therapeutics schedules Type C meeting with FDA for trial of CT1812 - TheFly
- 4 weeks ago - Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB - GlobeNewsWire
- 7 weeks ago - Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference - GlobeNewsWire